Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ProMIS Neurosciences Inc. - Common Shares (NQ: PMN )

2.132 +0.082 (+3.98%)
Streaming Delayed Price Updated: 9:51 AM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,316
Open 2.000
Bid (Size) 1.950 (13)
Ask (Size) 2.120 (10)
Prev. Close 2.050
Today's Range 2.000 - 2.132
52wk Range 0.9500 - 8.950
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic... 
Via Benzinga
Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70% to 16,288.03. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures US Equities

Performance

YTD
+53.40%
+53.40%
1 Month
+17.12%
+17.12%
3 Month
+2.48%
+2.48%
6 Month
+11.88%
+11.88%
1 Year
-66.36%
-66.36%

More News

Read More
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
From ProMIS Neurosciences Inc.
Via GlobeNewswire
PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q4 2023
Via InvestorPlace
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
ProMIS Neurosciences Issues Letter to Shareholders
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences, Inc. Announces Leadership Transition
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Publication on Novel Target for ALS
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 3, 2023
Via Benzinga
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Crude Oil Falls; Dick's Sporting Goods Earnings Miss Views
Via Benzinga
Topics Earnings Stocks
Exposures Financial Fossil Fuels US Equities
Why ProMIS Neurosciences Shares Are Trading Higher By 33%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Macy's Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Exposures Product Safety
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.